Xtandi 40 MG capsule 120S
Ended Awarded Last action
- Contract number
- SPE2DR26FFBZ4
- Awardee
-
DMS Pharmaceutical Group Inc. UEI PX72BSBQTKJ3
- Awarding agency
-
Defense Logistics Agency
Department of Defense
- Obligated
- $42,553
Award facts
- Contract value 100% obligated
- $42,553.40 Current and potential, with all options
- Completion date 100% complete
- Current and potential, with all options
- NAICS code
- 424210 Drugs and Druggists' Sundries Merchant Wholesalers
- PSC
- 6505 Drugs And Biologicals
- Set-aside
- No set-aside
- Competition
- Full and Open Competition Negotiated Proposal / Quote
- Pricing
- Firm Fixed Price
- Place of performance
- Park Ridge, IL 60068, USA
Award details come from SAM.gov/FPDS.
About this award
The Defense Logistics Agency awarded a delivery order valued at $42,553.40 to DMS Pharmaceutical Group Inc. for 120 capsules of XTANDI 40 MG, an oncology medication. This delivery order was issued under the Pharmaceutical Prime Vendor Global Program Generation V (PPV-G GEN V) initiative, a $30.3 billion acquisition strategy that establishes multiple regional prime vendor contractors to supply pharmaceutical products to Department of Defense healthcare facilities worldwide. The award was issued on January 28, 2026, with an ultimate completion date of January 29, 2026, utilizing firm fixed-price pricing with no set-aside designation. DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler headquartered in Park Ridge, Illinois, holds the underlying indefinite delivery contract (SPE2DR) under PPV-G GEN V with a $499.999 billion ceiling value extending through December 31, 2036.
DMS Pharmaceutical Group's selection reflects its established capability as a critical supplier within the federal pharmaceutical supply chain, supported by substantial recent contracting activity with the Defense Logistics Agency's Medical Supply Chain division. The company's extensive product portfolio encompasses branded and generic prescription medications, biologics, vaccines, specialty pharmaceuticals, and medical consumables, with delivery orders historically ranging from under $100 to over $115,000. As a single-award prime vendor contractor, DMS Pharmaceutical Group operates without identified subcontractors and serves as a key provider supporting recurring medical supply needs across the global Department of Defense healthcare system.
Quick answers
Who was awarded contract SPE2DR26FFBZ4?
SPE2DR26FFBZ4 was awarded to DMS Pharmaceutical Group Inc. by Defense Logistics Agency (Department of Defense) on January 28, 2026.
How much is contract SPE2DR26FFBZ4 worth?
The government has obligated $42,553 on SPE2DR26FFBZ4.
Is contract SPE2DR26FFBZ4 an order under another contract?
Yes. SPE2DR26FFBZ4 is a delivery order under SPE2DR25D9239, an indefinite delivery contract.
Was contract SPE2DR26FFBZ4 competed?
The extent of competition for SPE2DR26FFBZ4 was full and open competition.
On GovTribe
See this award's full record
- Every transaction and funding action
- The awardee's other awards and teaming partners
- Similar awards and recompete opportunities
- Ask GovTribe AI about this award